Literature DB >> 21533760

Adjuvant low single dose cisplatin-based concurrent radiochemotherapy of oral cavity and oropharynx carcinoma: impact of extracapsular nodal spread on distant metastases.

Thomas Kuhnt1, Ulf Klockenbrink, Stephan Knipping, Juergen Lautermann, Karen Kriese, Andreas Wienke, Guido Hildebrandt, Steffen Hauptmann.   

Abstract

BACKGROUND: The aim of this study was to analyze the prognostic importance of extracapsular nodal spread (ECS) in patients with locally advanced squamous cell carcinoma (SCC) of the oral cavity or oropharynx, and the impact of adjuvant low single dose cisplatin-based radiochemotherapy on distant metastases-free survival (DMFS). PATIENTS AND METHODS: The study population was selected from 195 patients with high-risk oral cavity or oropharyngeal cancer, who had either adjuvant radiotherapy (RT) or radiochemotherapy (RCT) between January 1, 1997 and December 31, 2006, at the University Clinic of Radiation Oncology of the Martin-Luther-University Halle-Wittenberg. A total of 42 matched pairs of patients with UICC stage III-IVa,b disease were analyzed. The patients were matched (one to one) according to tumor site, sex, T stage, N stage, ECS, resection margin status, and Karnofsky performance status. To analyze the correlation between the treatment modality (RT vs. RCT) and the impact of ECS on DMFS, the Cox proportional hazard model was used. Survival rates were calculated using the Kaplan-Meier method.
RESULTS: There was a strong correlation between the degree of nodal involvement and ECS (pN1: 33%; pN2b: 45%; pN2c: 71%). Moreover, the 5-year locoregional control rates (LC) in patients with ECS were 76% vs. 63% (n.s.) for RT and RCT, respectively. However, for patients without ECS, the LC was more favorable after RCT (RT vs. RCT: 62% vs. 88%, p < 0.05). DMFS again was better after RT, and this observation was independent of the presence or absence of ECS. Finally, in multivariate analyses, the presence of ECS significantly decreased the DMFS (p = 0.04, hazard ratio (HR) 2.64).
CONCLUSIONS: Patients with ECS have an increased risk of distant metastases. Adjuvant low single dose cisplatin-based concurrent chemotherapy seems to have no influence on occult microscopic systemic disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21533760     DOI: 10.1007/s00066-011-2186-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  19 in total

Review 1.  Head and neck cancer.

Authors:  A Forastiere; W Koch; A Trotti; D Sidransky
Journal:  N Engl J Med       Date:  2001-12-27       Impact factor: 91.245

2.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

Authors:  Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

3.  Extracapsular spread of squamous cell carcinoma in neck lymph nodes: prognostic factor of laryngeal cancer.

Authors:  H Hirabayashi; K Koshii; K Uno; H Ohgaki; Y Nakasone; T Fujisawa; N Syouno; T Hinohara; K Hirabayashi
Journal:  Laryngoscope       Date:  1991-05       Impact factor: 3.325

4.  Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study.

Authors:  D T Huang; C R Johnson; R Schmidt-Ullrich; M Grimes
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

5.  Supraglottic carcinoma: impact of radiation therapy on outcome of patients with positive margins and extracapsular nodal disease.

Authors:  V R Devineni; J R Simpson; D Sessions; J G Spector; R Hayden; J Fredrickson; B Fineberg
Journal:  Laryngoscope       Date:  1991-07       Impact factor: 3.325

6.  Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).

Authors:  Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre
Journal:  Head Neck       Date:  2005-10       Impact factor: 3.147

7.  Prediction of distant metastasis in head neck cancer patients: implications for induction chemotherapy and pre-treatment staging?

Authors:  Gabriela Studer; Burkhardt Seifert; Christoph Glanzmann
Journal:  Strahlenther Onkol       Date:  2008-11-19       Impact factor: 3.621

8.  Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis.

Authors:  Diana Steinmann; Bettina Cerny; Johann Hinrich Karstens; Michael Bremer
Journal:  Strahlenther Onkol       Date:  2009-10-06       Impact factor: 3.621

9.  Evaluation of prognostic factors and two radiation techniques in patients treated with surgery followed by radio(chemo)therapy or definitive radio(chemo)therapy for locally advanced head-and-neck cancer.

Authors:  Dirk Rades; Monika Stoehr; Thekla Meyners; Guenther Bohlen; Roger Nadrowitz; Juergen Dunst; Steven E Schild; Junes Wroblewski; Dirk Albers; Rainer Schmidt; Winfried Alberti; Silke Tribius
Journal:  Strahlenther Onkol       Date:  2008-04       Impact factor: 3.621

10.  Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: preliminary report of a randomized trial.

Authors:  J M Bachaud; J M David; G Boussin; N Daly
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-02       Impact factor: 7.038

View more
  6 in total

1.  Computed tomography detection of extracapsular spread of squamous cell carcinoma of the head and neck in metastatic cervical lymph nodes.

Authors:  Joshua A Carlton; Adam W Maxwell; Lyndsey B Bauer; Sara M McElroy; Lester J Layfield; Humera Ahsan; Ajay Agarwal
Journal:  Neuroradiol J       Date:  2017-03-08

2.  Survival of patients with head and neck cancer. Impact of physical status and comorbidities.

Authors:  F Sadat; A Wienke; J Dunst; T Kuhnt
Journal:  Strahlenther Onkol       Date:  2011-12-23       Impact factor: 3.621

3.  Efficacy and toxicity of (chemo)radiotherapy for primary subglottic cancer.

Authors:  M Hata; T Taguchi; I Koike; G Nishimura; M Takahashi; M Komatsu; D Sano; K Odagiri; Y Minagawa; T Inoue
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

4.  Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function.

Authors:  M Hata; I Koike; J Maegawa; A Kaneko; K Odagiri; T Kasuya; Y Minagawa; H Kaizu; Y Mukai; T Inoue
Journal:  Strahlenther Onkol       Date:  2012-10-28       Impact factor: 3.621

5.  MicroRNA-17-5p post-transcriptionally regulates p21 expression in irradiated betel quid chewing-related oral squamous cell carcinoma cells.

Authors:  S-Y Wu; K-C Lin; J-F Chiou; S-C Jeng; W-H Cheng; C-I Chang; W-C Lin; L-L Wu; H-L Lee; R-J Chen
Journal:  Strahlenther Onkol       Date:  2013-06-20       Impact factor: 3.621

6.  MicroRNA-17-5p regulated apoptosis-related protein expression and radiosensitivity in oral squamous cell carcinoma caused by betel nut chewing.

Authors:  Szu-Yuan Wu; Alexander T H Wu; Shing-Hwa Liu
Journal:  Oncotarget       Date:  2016-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.